Skip to main content

Insulin Sensitivity

1
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
RosiglitazonePhase 4
Extended-release nicotinic acid versus placeboN/A
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
ControlN/A1 trial
Active Trials
NCT04267705Active Not Recruiting103Est. Jan 2026
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Hi GIN/A1 trial
Active Trials
NCT03410719Completed166Est. Mar 2020
Innovation Pharmaceuticals
1 program
Negative energy balanceN/A1 trial
Active Trials
NCT03264001Unknown61Est. Dec 2018
Alliance Pharmaceuticals
1 program
PotatoN/A1 trial
Active Trials
NCT03689738Completed24Est. Feb 2019
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Sleep ExtensionN/A1 trial
Active Trials
NCT03500458Active Not Recruiting75Est. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesControl
Colorado TherapeuticsSleep Extension
Alliance PharmaceuticalsPotato
Purdue PharmaHi GI
Innovation PharmaceuticalsNegative energy balance

Clinical Trials (5)

Total enrollment: 429 patients across 5 trials

NCT04267705Human BioSciencesControl

Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human

Start: Feb 2020Est. completion: Jan 2026103 patients
N/AActive Not Recruiting
NCT03500458Colorado TherapeuticsSleep Extension

Impact of Sleep Extension in Adolescents

Start: Oct 2018Est. completion: May 202575 patients
N/AActive Not Recruiting
NCT03689738Alliance PharmaceuticalsPotato

Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety

Start: Sep 2018Est. completion: Feb 201924 patients
N/ACompleted
NCT03410719Purdue PharmaHi GI

Mediterranean Style Diet and Low Glycemic Responses

Start: Jan 2018Est. completion: Mar 2020166 patients
N/ACompleted
NCT03264001Innovation PharmaceuticalsNegative energy balance

Effects of Progressive Negative Energy Balance on Glucose Tolerance, Insulin Sensitivity, and Beta-cell Function

Start: Apr 2017Est. completion: Dec 201861 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.